In melanoma or NSCLC, specific inhibitors of BRAF kinase Vemurafenib and Dabrafenib and MEK inhibitors Binimetinib and Trametinib are used only in BRAF-mutated tumors. This evidence concerns the gene BRAF and non-small cell lung carcinoma.